World's Best Scientists 2026 revealed!
Stephen E. Sallan

Stephen E. Sallan

D-Index & Metrics

Medicine

D-Index
121
Citations
48026
World Ranking
3635
National Ranking
2007

Stephen E. Sallan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stephen E. Sallan sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 412 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stephen E. Sallan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stephen E. Sallan sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 121 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Stephen E. Sallan is affiliated with Harvard University in the United States and has contributed extensively to medical research, particularly within the field of medicine. Their work primarily focuses on topics including acute lymphoblastic leukemia research, childhood cancer survivors' quality of life, adolescent and pediatric healthcare, lymphoma diagnosis and treatment, acute myeloid leukemia research, cancer risks and factors, and folate and B vitamins research.

The scientist has published research prominently in several venues, with multiple papers appearing in "Blood," "Pediatric Blood & Cancer," "Journal of Clinical Oncology," "Blood Advances," and "Leukemia." Their publication record includes 55 works in medicine, with notable subfields being public health, environmental and occupational health, pediatrics, perinatology and child health, oncology, speech and hearing, and pathology and forensic medicine.

Stephen E. Sallan frequently collaborates with several coauthors, including Lewis B. Silverman, Yael Flamand, Lynda M. Vrooman, Andrew E. Place, and Kara M. Kelly, having coauthored numerous publications with each.

Recent significant papers by Stephen E. Sallan include:

  • Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001, 2021, Journal of Clinical Oncology
  • Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001, 2020, Pediatric Blood & Cancer
  • Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials, 2023, Blood Advances
  • Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort, 2020, Journal of Clinical Oncology
  • Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols, 2024, Leukemia

Their research topics cover:

  • Acute Lymphoblastic Leukemia research
  • Childhood Cancer Survivors' Quality of Life
  • Adolescent and Pediatric Healthcare
  • Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Cancer Risks and Factors
  • Folate and B Vitamins Research

Fields of study they have contributed to include:

  • Medicine

Subfields of study encompass:

  • Public Health, Environmental and Occupational Health
  • Pediatrics, Perinatology and Child Health
  • Oncology
  • Speech and Hearing
  • Pathology and Forensic Medicine

Frequent coauthors with multiple collaborations are:

  • Lewis B. Silverman
  • Yael Flamand
  • Lynda M. Vrooman
  • Andrew E. Place
  • Kara M. Kelly

Frequent publication venues include:

  • Blood
  • Pediatric Blood & Cancer
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia

Stephen E. Sallan is also recognized as a member of the Association of American Physicians.

Best Publications

  • Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia

    Todd R. Golub;Scott A. Armstrong;Stanley J. Korsmeyer

  • Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood

    Steven E. Lipshultz;Steven D. Colan;Richard D. Gelber;Antonio R. Perez-Atayde

  • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

    Lewis B. Silverman;Richard D. Gelber;Virginia Kimball Dalton;Barbara L. Asselin

  • Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

    M Smith;D Arthur;B Camitta;A J Carroll

  • Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

    Lipshultz Se;Lipsitz;Mone Sm;Goorin Am

  • Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia

    Steven E. Lipshultz;Stuart R. Lipsitz;Stephen E. Sallan;Virginia M. Dalton

  • An Oncogenic Super-Enhancer Formed Through Somatic Mutation of a Noncoding Intergenic Element

    Marc R. Mansour;Marc R. Mansour;Brian J. Abraham;Lars Anders;Alla Berezovskaya

  • Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.

    A. R. Perez-Atayde;S. E. Sallan;U. Tedrow;S. Connors

  • The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia

    Steven E. Lipshultz;Nader Rifai;Virginia M. Dalton;Donna E. Levy

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association

    Steven E. Lipshultz;M. Jacob Adams;Steven D. Colan;Louis S. Constine

  • Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

    Guo Wei;Guo Wei;David Twomey;David Twomey;Justin Lamb;Krysta Schlis

  • Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

    Clavell La;Gelber Rd;Cohen Hj;Hitchcock-Bryan S

  • Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

    Albert Moghrabi;Donna E. Levy;Barbara L. Asselin;Ronald Barr

  • Development of homozygosity for chromosome 11p markers in Wilms' tumour

    Stuart H. Orkin;Debra S. Goldman;Stephen E. Sallan

  • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

    Steven E Lipshultz;Rebecca E Scully;Stuart R Lipsitz;Stephen E Sallan;Stephen E Sallan

  • Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification

    Scott A Armstrong;Andrew L Kung;Andrew L Kung;Meghann E Mabon;Lewis B Silverman;Lewis B Silverman

  • High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

    Alejandro Gutierrez;Alejandro Gutierrez;Takaomi Sanda;Ruta Grebliunaite;Arkaitz Carracedo

  • Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation

    Adolfo A. Ferrando;Scott A. Armstrong;Donna S. Neuberg;Stephen E. Sallan

  • Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury

    Steven E. Lipshultz;Nader Rifai;Stephen E. Sallan;Stuart R. Lipsitz

Frequent Co-Authors

Lewis B. Silverman
Lewis B. Silverman Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Steven E. Lipshultz
Steven E. Lipshultz University at Buffalo, State University of New York
Richard D. Gelber
Richard D. Gelber Harvard University
Nancy J. Tarbell
Nancy J. Tarbell Harvard University
Steven D. Colan
Steven D. Colan Boston Children's Hospital
Stuart R. Lipsitz
Stuart R. Lipsitz Brigham and Women's Hospital
Jerome Ritz
Jerome Ritz Harvard University
Harvey J. Cohen
Harvey J. Cohen Duke University
Scott A. Armstrong
Scott A. Armstrong Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in a medical career but want flexible study options, there are several reputable online degrees to consider in the USA. Nursing is a rapidly growing field, and enrolling in online msn pmhnp programs allows you to specialize in psychiatric mental health while balancing work or family commitments.

For those drawn to the business side of healthcare, earning a health care administration online degree can open doors to management roles in hospitals, clinics, and insurance companies. If you’re seeking advanced leadership positions, consider a master's in healthcare administration online. These programs focus on healthcare policy, organizational behavior, and strategic decision-making.

Another pathway to leadership or advanced clinical roles is through cheap dnp online programs. With a Doctor of Nursing Practice degree, you’ll be prepared for top-level practice, research, or teaching positions in healthcare.

Each of these online options provides flexible learning, making it easier to advance your career in medicine or health-related fields while accommodating your lifestyle.

Best Scientists Citing Stephen E. Sallan

Trending Scientists

Recently Published Articles